Biocartis

Generaal De Wittelaan 11

2800 Mechelen

BE

Biocartis

Foundation date

02/07/2010

Sector

#Medical Technology

Subsector

Therapeutic areas

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.

Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Upcoming events

Latest news

  • Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®

    8 hours ago

  • S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities

    Tuesday August 2nd 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022

Jobs by Biocartis